©1996 by The American Society for Biochemistry and Molecular Biology, Inc.
P Purinergic Receptor Agonists Enhance cAMP Production in Madin-Darby Canine Kidney Epithelial Cells via an Autocrine/Paracrine Mechanism (*)

(Received for publication, August 30, 1995; and in revised form, November 20, 1995)

Steven R. Post J. Paul Jacobson Paul A. Insel (§)

From the Department of Pharmacology, University of California, San Diego, La Jolla, California 92093-0636

ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS AND DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES

ABSTRACT

Mechanisms of cross-talk between different classes of signaling molecules are inadequately understood. We have used clonal Madin-Darby canine kidney (MDCK-D(1)) epithelial cells as a model system to investigate the effects of extracellular nucleotides (e.g. ATP, UTP), which promote increase in activity of several phospholipases, on cAMP production. In contrast to observations in some other cell systems, ATP and UTP, acting via P(2) purinergic receptors, stimulated cAMP production in MDCK-D(1) cells. At maximally effective concentrations, ATP and UTP were not additive with the beta-adrenergic receptor agonist isoproterenol, but were synergistic with forskolin in increasing cAMP production, indicating that G is activated by these nucleotides. Additionally, we found that (a) nucleotide-induced increases in cAMP were blocked by indomethacin, a cyclooxygenase inhibitor, (b) arachidonic acid increased cellular cAMP levels in an indomethacin-sensitive fashion, and (c) PGE(2), the major metabolite of arachidonic acid, stimulated cAMP formation. Overall, our results suggest a mechanism by which extracellular nucleotides stimulate release of arachidonic acid which is metabolized to PGE(2) which, in turn, acts in an autocrine/paracrine fashion via prostaglandin receptors to activate G and increase cAMP. Based on the ability of extracellular nucleotides to stimulate the formation and release of prostaglandins in MDCK-D(1) epithelial and other cells, we hypothesize that receptor-mediated prostaglandin release may be a general mechanism that regulates cAMP formation in many types of cells.


INTRODUCTION

Extracellular ATP, an important extracellular signaling molecule, is stored and released from sympathetic neurotransmitter vesicles and from stressed/damaged cells. Receptors that interact specifically with ATP (classified as P(2) purinergic receptors) are present in many tissues and cell types(1, 2, 3, 4) . Two subclasses of G protein-coupled P(2) purinergic receptors include P and P receptors which differ in their specificity for nucleotide. In particular, P receptors bind ATP, while P receptors respond to both ATP and UTP(2, 5) . Additionally, ATP can be metabolized to adenosine, the agonist for P(1) purinergic receptors.

Interaction of extracellular nucleotides with P(2) purinergic receptors elicit a range of intracellular signaling responses. The most common response elicited by ATP is the activation of phospholipase C with subsequent increases in 1,4,5-inositol trisphosphate formation, diacylglycerol production, increased intracellular Ca, and activation of protein kinase C (PKC) (^1)(5, 6, 7, 8) . Activation of phospholipase A(2) and phospholipase D has also been reported to occur in response to nucleotides(9, 10, 11) . In addition, in rat hepatocytes, FRTL-5 thyroid cells, mouse ventricular myocytes, and C6-glioma cells, extracellular ATP inhibits cAMP production by both pertussis toxin-sensitive and insensitive pathways (8, 12, 13, 14, 15, 16, 17) .

MDCK cells are a well differentiated epithelial cell line and have been widely used as a model system for studying the regulation of epithelial cell function(18, 19, 20) . In these cells, cAMP regulates Cl ion secretion, polarized vesicle transport, and Na/K ATPase activity(21, 22, 23, 24) . MDCK-D(1) cells, a clonal line derived from parental cells (25, 26) , appear to express both P and P purinergic receptors(10, 27) . Because of the importance of cAMP in regulating epithelial cell function and the potential interaction between P(2) purinergic receptor response pathways and the adenylyl cyclase pathway, we examined the effect of extracellular nucleotides on cAMP generation in MDCK-D(1) cells. In contrast to observations in other cell lines, we found that both ATP and UTP stimulated cAMP production in MDCK-D(1) cells. Several mechanisms relating phospholipase activation to modulation of cAMP accumulation could explain this result. In particular, increases in Ca or PKC activity following phospholipase C activation can alter adenylyl cyclase activity. In this study, however, we demonstrate that nucleotide-induced phospholipase activation leads to increased levels of cAMP by the release of arachidonic acid, and in turn, cyclooxygenase-derived products. We propose that utilization of this autocrine/paracrine pathway may be a general mechanism for regulating cAMP production in epithelial cells and other cell types.


MATERIALS AND METHODS

Cell Culture

MDCK-D(1) cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% serum as described previously(25, 26) . Cells were used in assays at 60-80% confluence. At cell densities greater than this, basal cAMP levels were increased.

Measurement of cAMP Accumulation

Prior to treatment of cells, growth medium was removed and cells were equilibrated for 30 min at 37 °C in serum-free Dulbecco's modified Eagle's medium containing 20 mM HEPES buffer (DMEH; pH 7.4). Subsequently, cells were incubated in fresh HEPES-buffered Dulbecco's modified Eagle's medium and various agents as described in the figure legends. Unless otherwise indicated, incubations with agonist were conducted for 5 min at 37 °C in the presence of 200 µM IBMX, a phosphodiesterase inhibitor, and terminated by aspiration of medium and addition of 7.5% trichloroacetic acid. Trichloroacetic acid extracts were frozen (-20 °C) until assay. Intracellular cAMP levels were determined by radioimmunoassay (Calbiochem) of trichloroacetic acid extracts following acetylation according to manufacturer's protocol. The sensitivity of this assay allowed for large dilution of trichloroacetic acid extracts such that ether extraction of trichloroacetic acid was unnecessary. Production of cAMP was normalized to the amount of acid-insoluble protein assayed by the Bio-Rad protein assay.

Chemicals

Chemicals were purchased from the following sources: forskolin and anti-cAMP antibody were from Calbiochem. I-cAMP from DuPont NEN, and all other reagents were from Sigma.


RESULTS AND DISCUSSION

We assessed the ability of various P(2) receptor and P(1) receptor agonists to affect cAMP accumulation in MDCK-D(1) cells. As shown in Fig. 1a, both ATP and UTP stimulated cAMP formation. It is unlikely that this response to ATP resulted from breakdown to adenosine and activation of P(1) purinergic receptors, since adenosine failed to alter cAMP production, whereas ATPS, a nonhydrolyzable ATP analog, stimulated cAMP formation to the same extent as ATP. This suggested that extracellular nucleotides acting at P(2) purinergic receptors were mediating cAMP formation. The ability of UTP, a P receptor agonist, and 2-methylthio-ATP, a P receptor agonist, to increase cAMP indicate that both P and P receptors are positively coupled to adenylyl cyclase activation in MDCK-D(1) cells. P(2) purinergic receptor-mediated stimulation of cAMP formation was concentration-dependent (Fig. 1b), exhibiting an average EC for UTP and ATP of 4.2 ± 1.8 µM and 22.5 ± 1.1 µM, respectively. The ability of nucleotides to stimulate cAMP production in MDCK-D(1) cells occurred at concentrations previously shown to activate phospholipase-linked pathways in this and other cell systems(10, 12, 14, 28) . At maximally effective concentrations, UTP-stimulated cAMP formation was typically not as great as that occurring with ATP; a result consistent with the interaction of ATP with multiple (presumably both P and P) receptor populations.


Figure 1: P(2) receptor agonists increase cAMP in MDCK cells. MDCK-D(1) cells were treated as described under ``Materials and Methods.'' a, cells were incubated in the presence or absence of the indicated nucleotide (100 µM), adenosine (Adn; 100 µM), or isoproterenol (Iso; 10 µM). b, cells were stimulated with the indicated concentrations of ATP and UTP. Incubations were for 5 min in the presence of 200 µM isobutylmethylxanthine. Cells were treated and cAMP assayed as described under ``Materials and Methods.'' Data represent the mean ± S.E. of triplicate determinations from a representative experiment with similar results obtained in at least three separate experiments.



In general, P and P purinergic receptors mediate the activation of phospholipase C with subsequent increases cellular Ca levels(5, 6, 7, 8) . Increased intracellular Ca is known to stimulate adenylyl cyclase through a variety of mechanisms, including interaction with calmodulin and activation of PKC(29, 30, 31, 32) . Since ATP and UTP increase intracellular Ca ion concentration in MDCK-D(1) cells(27) , it is possible that nucleotides stimulate cAMP production by a Ca-dependent process. Because Ca/calmodulin-stimulated adenylyl cyclase isoforms, types I and VIII, have not been detected in kidney(33, 34) , it is unlikely that the nucleotide-stimulated increase in cAMP in MDCK cells results from a direct interaction of Ca/calmodulin with adenylyl cyclase. We therefore examined the extent to which activation of PKC could mimic the effect of nucleotides on cAMP production in these cells. As shown in Fig. 2, treatment of cells with the phorbol ester, phorbol 12-myristate 13-acetate, for 10 min had no effect on basal or forskolin-stimulated cAMP accumulation. Since protein kinase C-dependent modulation of the activity of certain isoforms of adenylyl cyclase is conditional upon G activation(35, 36) , we examined the effect of nucleotides on beta-adrenergic receptor-stimulated cAMP production. As shown in Fig. 3, ATP and UTP were not additive with the beta-adrenergic receptor agonist, isoproterenol, in increasing cAMP formation. It therefore appears that in MDCK-D(1) cells, PKC activation is not directly responsible for the nucleotide-mediated increase in cAMP.


Figure 2: Activation of PKC does not mimic nucleotide effect on cAMP production. MDCK-D(1) cells were preincubated in the presence or absence of 50 ng/ml phorbol 12-myristate, 13-acetate (PMA), a PKC activator, for 10 min at 37 °C. Subsequently, isobutylmethylxanthine and either 100 µM nucleotide or 1 µM forskolin (Fsk) was added and incubations continued as described under ``Materials and Methods.'' The data represent the mean ± S.E. of triplicate determinations with similar results obtained in multiple experiments.




Figure 3: Nucleotide- and PGE(2)-stimulated cAMP production is synergistic with forskolin but not with isoproterenol. Cells were stimulated with buffer, 100 µM nucleotide, 10 µM isoproterenol (Iso), 1 µM forskolin (Fsk), or combinations thereof. The inset shows cAMP formation in response to varying concentrations of PGE(2) in the presence or absence of 0.1 µM forskolin. The data represent the mean ± S.E. of triplicate determinations from a representative experiment with similar results obtained in at least three separate experiments.



Signaling pathways utilized by P(2) purinergic receptors on MDCK-D(1) cells were investigated further in experiments that examined cAMP formation following the simultaneous addition of nucleotides with either isoproterenol or forskolin. As shown in Fig. 3, when tested at maximally effective concentrations, ATP and UTP were not additive with each other or with the response elicited by isoproterenol. This lack of additivity is consistent with the utilization of a common pathway by both P(2) purinergic receptors and beta-adrenergic receptors. In contrast, nucleotide- and isoproterenol-stimulated cAMP production were both synergistic with forskolin. As shown here in studies with isoproterenol and PGE(2) ( Fig. 3and inset) and as demonstrated previously(37, 38, 39) , synergistic effects of such agonists and forskolin in stimulating cAMP production is associated with activation of G, probably by enhancing the ability of G to interact with adenylyl cyclase(39, 40) . Thus, it appears that the ATP and UTP-mediated increase in cAMP production involves G activation.

To date, however, there is no evidence for the interaction of P(2) purinergic receptors directly with G(s). We hypothesized therefore, that the activation of G might be secondary to purinergic receptor-mediated stimulation of arachidonic acid release and the subsequent formation of arachidonic acid metabolites, perhaps those derived from the action of cyclooxygenase. In this regard, we have found that activation of phospholipases, in particular phospholipase A(2), in MDCK-D(1) cells results in the release of arachidonic acid and, in turn, to the formation of PGE(2)(41) . Furthermore, PGE(2) release is inhibited by indomethacin, a cyclooxygenase inhibitor(42) . Since both ATP and UTP stimulate the release of arachidonic acid in these cells(10, 27) , it seemed possible that P(2) purinergic receptor-mediated cAMP production was secondary to the metabolism of arachidonic acid. Indeed, as shown in Fig. 4, arachidonic acid stimulated cAMP formation with a time course that parallels that of nucleotide-mediated activation. For both exogenous arachidonic acid and nucleotides, maximal cAMP levels were obtained by 5 min. The effect of arachidonic acid to increase cAMP formation occurred at concentrations between 1 and 10 µM, and importantly, the ability of arachidonic acid to stimulate cAMP accumulation was completely inhibited by 1 µM indomethacin (Fig. 5a). This result led us to predict that cyclooxygenase activity and presumably prostaglandin produced from arachidonic acid might be responsible for the effect of ATP and UTP to stimulate cAMP production. Results presented in Fig. 5b confirm this prediction in that nucleotide-stimulated cAMP production, like that elicited by arachidonic acid, was inhibited by indomethacin. Taken together, our results indicate that in MDCK-D(1) cells cyclooxygenase products, most likely PGE(2), produced following P(2) purinergic receptor activation of phospholipases mediate the cAMP response observed in response to extracellular nucleotides.


Figure 4: Nucleotides, arachidonic acid, and PGE(2) show similar kinetics of cAMP production in MDCK-D(1) cells. Cells were stimulated with 100 µM nucleotide, 1 µM arachidonic acid (AA), or 0.1 µM PGE(2) for the indicated period of time. The dotted line represents cAMP production in unstimulated cells. The data represent the mean ± S.E. of duplicate determinations from two individual experiments.




Figure 5: Inhibition of cyclooxygenase blocks nucleotide- and arachidonic acid-stimulated cAMP production. a, cells were preincubated in the presence or absence of 1 µM indomethacin, a cyclooxygenase inhibitor, for 15 min prior to incubation for 7 min with the indicated concentrations of arachidonic acid. b, after a 15 min preincubation in the presence or absence of 1 µM indomethacin, cells were stimulated for 7 min with buffer, 100 µM ATP, 100 µM UTP, or 0.3 µM forskolin (Fsk). The data represent the mean ± S.E. of triplicate determinations from a representative experiment with similar results obtained in at least three separate experiments.



Modulation of adenylyl cyclase activity by extracellular nucleotides has been previously noted, but, in general, the effect of nucleotides on cAMP accumulation is inhibitory. Roles for G(i) activation, Ca, and PKC have been implicated in ATP-mediated inhibition of cAMP production(8, 14, 16, 17) . Notwithstanding these inhibitory effects on adenylyl cyclase, there are reports of extracellular nucleotide-mediated increases in cAMP formation. For example, in bovine aortic endothelial cells, ATP results in a 3-fold increase in cAMP production and a greater than additive increase when added together with forskolin(43) . The mechanism by which ATP elicited this response appears to involve both PKC activation and ATP interaction with methylxanthine-sensitive receptors. Similarly, in L cells and adrenal medullary endothelial cells, ATP sensitizes adenylyl cyclase to stimulation by hormones and forskolin(28, 44) . Sensitization of adenylyl cyclase to activation by G-linked receptor agonists or forskolin have been described for PKC-dependent modulation of distinct adenylyl cyclase isoforms(35, 36, 45, 46) . It therefore seems likely that in aortic endothelial cells, L cells, and adrenal medullary cells PKC mediates the ability of P(2) purinergic receptor agonists to increase adenylyl cyclase activity. In Swiss 3T3 fibroblasts and human A431 epidermoid carcinoma cells, however, ATP-stimulated cAMP production is sensitive to cyclooxygenase inhibitors(47, 48) . This effect is associated with the ability of ATP to stimulate mitogenesis in these cells(48, 49) . In contrast to results presented here, in both 3T3 and A431 cells there is an initial delay of 15 min before cAMP increases are observed, and maximal cAMP accumulation is not achieved until 45 min after addition of ATP. Therefore, it seems less likely that nucleotide-mediated cAMP formation in 3T3 cells or A431 cells serves a role in rapid alterations of cellular responses.

Our results in MDCK-D(1) cells demonstrate that extracellular nucleotides rapidly stimulate cAMP formation by a mechanism involving the liberation of arachidonic acid, and production of prostaglandin, presumably PGE(2). PGE(2) then acts in an autocrine/paracrine manner at a prostaglandin receptor to activate G and subsequently adenylyl cyclase. The ability of P(2)-nucleotide receptors to stimulate cAMP by this mechanism, therefore, depends on several properties. First, phospholipases must be activated and arachidonic acid must be released in quantities sufficient for substantial prostaglandin formation. Second, cyclooxygenase must be present and active in the time frame during which arachidonic acid is available. Third, the cells must possess prostaglandin receptors, which are positively coupled to adenylyl cyclase. In MDCK-D(1) cells, as well as in 3T3 and A431 cells, these criteria have been fulfilled. We predict that other cell types will show similar features.

Thus, extracellular nucleotides released from granules or in other settings, such as cell damage, can regulate cAMP formation in a variety of cell types. In many cases this effect is inhibitory. However, depending on cell type, nucleotides can stimulate cAMP formation by at least two different mechanisms. In aortic endothelial cells, L cells, and adrenal medullary cells this stimulation appears to be mediated by PKC. In MDCK-D(1) epithelial, fibroblast, and epidermoid carcinoma cells, nucleotide-stimulated cAMP formation results from the cyclooxygenase-dependent metabolism of arachidonic acid. In this way, P(2) receptors can regulate both rapid (e.g. secretion) and long term (e.g. mitogenesis) cAMP-dependent cell functions.


FOOTNOTES

*
This work was supported by Grants GM 40781, GM 31987, HL 53773, and HL 35018 from National Institutes of Health and Postdoctoral Fellowship GM 16172 from National Institutes of Health (to S. R. P.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§
To whom correspondence should be addressed. Tel.: 619-534-2295; Fax: 619-534-6833.

(^1)
The abbreviations used are: PKC, protein kinase C; MDCK-D(1), clonal Madin-Darby canine kidney cells; ATPS, adenosine 5`-O-(thiotriphosphate); PGE(2), prostaglandin E(2).


ACKNOWLEDGEMENTS

-We thank Elizabeth Peters and David Dirig for their initial contributions to this project, Rachel Mastandrea for help in conducting cAMP assays, and Kelly Bell for technical assistance.


REFERENCES

  1. Fredholm, B. B., Abbracchio, M. P., Burnstock, G., Daly, J. W., Harden, T. K., Jacobson, K. A., Leff, P., and Williams, M. (1994) Pharmacol. Rev. 46, 143-156 [Medline] [Order article via Infotrieve]
  2. Dubyak, G. R., and El Moatassim, C. (1993) Am. J. Physiol. 265, C577-C606
  3. Burnstock, G., and Kennedy, C. (1985) Gen. Pharmacol. 16, 433-440 [Medline] [Order article via Infotrieve]
  4. Harden, T. K., Boyer, J. L., and Nicholas, R. A. (1995) Annu. Rev. Pharmacol. Toxicol. 35, 541-579 [CrossRef][Medline] [Order article via Infotrieve]
  5. Boarder, M. R., Weisman, G. A., Turner, J. T., and Wilkinson, G. F. (1995) Trends Pharmacol. Sci. 16, 133-139 [CrossRef][Medline] [Order article via Infotrieve]
  6. Boyer, J. L., Downes, C. P., and Harden, T. K. (1989) J. Biol. Chem. 264, 884-890 [Abstract/Free Full Text]
  7. Dubyak, G. R. (1986) Arch. Biochem. Biophys. 245, 84-95 [Medline] [Order article via Infotrieve]
  8. Munshi, R., DeBernardi, M. A., and Brooker, G. (1993) Mol. Pharmacol. 44, 1185-1191 [Abstract]
  9. Lazarowski, E. R., Boucher, R. C., and Harden, T. K. (1994) Am. J. Physiol. 266, C406-C415
  10. Balboa, M. A., Firestein, B. L., Godson, C., Bell, K. S., and Insel, P. A. (1994) J. Biol. Chem. 269, 10511-10516 [Abstract/Free Full Text]
  11. Pfeilschifter, J., and Merriweather, C. (1993) Br. J. Pharmacol. 110, 847-853 [Abstract]
  12. Keppens, S., Vandekerckhove, A., and De Wulf, H. (1992) Br. J. Pharmacol. 105, 475-479 [Abstract]
  13. Okajima, F., Tokumitsu, Y., Kondo, Y., and Ui, M. (1987) J. Biol. Chem. 262, 13483-13490 [Abstract/Free Full Text]
  14. Okajima, F., Sato, K., Nazarea, M., Sho, K., and Kondo, Y. (1989) J. Biol. Chem. 264, 13029-13037 [Abstract/Free Full Text]
  15. Yamada, M., Hamamori, Y., Akita, H., and Yokoyama, M. (1992) Circ. Res. 70, 477-485 [Abstract]
  16. Valeins, H., Merle, M., and Labouesse, J. (1992) Mol. Pharmacol. 42, 1033-1041 [Abstract]
  17. Boyer, J. L., Lazarowski, E. R., Chen, X. H., and Harden, T. K. (1993) J. Pharmacol. Exp. Ther. 267, 1140-1146 [Abstract]
  18. Simmons, N. L. (1982) Gen. Pharmacol. 13, 287-291 [Medline] [Order article via Infotrieve]
  19. Simmons, N. L., Brown, C. D., and Rugg, E. L. (1984) Fed. Proc. 43, 2225-2229 [Medline] [Order article via Infotrieve]
  20. Insel, P. A., Weiss, B. A., Slivka, S. R., Howard, M. J., Waite, J. J., and Godson, C. A. (1991) Biochem. Soc. Trans. 19, 329-333 [Medline] [Order article via Infotrieve]
  21. Simmons, N. L. (1991) J. Physiol. (Lond.) 432, 459-472
  22. Pimplikar, S. W., and Simons, K. (1994) J. Biol. Chem. 269, 19054-19059 [Abstract/Free Full Text]
  23. Taub, M. L., Wang, Y., Yang, I. S., Fiorella, P., and Lee, S. M. (1992) J. Cell. Physiol. 151, 337-346 [Medline] [Order article via Infotrieve]
  24. Takemoto, F., Cohen, H. T., Satoh, T., and Katz, A. I. (1992) Pflugers Arch. 421, 302-306 [Medline] [Order article via Infotrieve]
  25. Meier, K. E., Snavely, M. D., Brown, S. L., Brown, J. H., and Insel, P. A. (1983) J. Cell Biol. 97, 405-415 [Abstract]
  26. Meier, K. E., Sperling, D. M., and Insel, P. A. (1985) Am. J. Physiol. 249, C69-C77
  27. Firestein, B. L., Llopis, J., and Insel, P. A. (1995) FASEB J. 9, A553
  28. Allsup, D. J., and Boarder, M. R. (1990) Mol. Pharmacol. 38, 84-91 [Abstract]
  29. Wayman, G. A., Impey, S., Wu, Z., Kindsvogel, W., Prichard, L., and Storm, D. R. (1994) J. Biol. Chem. 269, 25400-25405 [Abstract/Free Full Text]
  30. Taussig, R., Tang, W. J., Hepler, J. R., and Gilman, A. G. (1994) J. Biol. Chem. 269, 6093-6100 [Abstract/Free Full Text]
  31. Taussig, R., and Gilman, A. G. (1995) J. Biol. Chem. 270, 1-4 [Free Full Text]
  32. Cooper, D. M., Mons, N., and Karpen, J. W. (1995) Nature 374, 421-424 [CrossRef][Medline] [Order article via Infotrieve]
  33. Xia, Z., Choi, E. J., Wang, F., Blazynski, C., and Storm, D. R. (1993) J. Neurochem. 60, 305-311 [Medline] [Order article via Infotrieve]
  34. Krupinski, J., Lehman, T. C., Frankenfield, C. D., Zwaagstra, J. C., and Watson, P. A. (1992) J. Biol. Chem. 267, 24858-24862 [Abstract/Free Full Text]
  35. Choi, E. J., Wong, S. T., Dittman, A. H., and Storm, D. R. (1993) Biochemistry 32, 1891-1894 [Medline] [Order article via Infotrieve]
  36. Morimoto, B. H., and Koshland, D. E., Jr. (1994) J. Biol. Chem. 269, 4065-4069 [Abstract/Free Full Text]
  37. Darfler, F. J., Mahan, L. C., Koachman, A. M., and Insel, P. A. (1982) J. Biol. Chem. 257, 11901-11907 [Free Full Text]
  38. Jasper, J. R., Michel, M. C., and Insel, P. A. (1990) Mol. Pharmacol. 37, 44-49 [Abstract]
  39. Sutkowski, E. M., Tang, W. J., Broome, C. W., Robbins, J. D., and Seamon, K. B. (1994) Biochemistry 33, 12852-12859 [Medline] [Order article via Infotrieve]
  40. Laurenza, A., and Seamon, K. B. (1991) Methods Enzymol. 195, 52-65 [Medline] [Order article via Infotrieve]
  41. Slivka, S. R., and Insel, P. A. (1988) J. Biol. Chem. 263, 14640-14647 [Abstract/Free Full Text]
  42. Vane, J. R. (1971) Nature New Biol. 231, 232-235 [Medline] [Order article via Infotrieve]
  43. Cote, S., Van, S. J., and Boeynaems, J. M. (1993) Am. J. Physiol. 264, H1498-H1503
  44. Johnson, J. A., Friedman, J., Halligan, R. D., Birnbaumer, M., and Clark, R. B. (1991) Mol. Pharmacol. 40, 539-546 [Abstract]
  45. Yoshimura, M., and Cooper, D. M. (1993) J. Biol. Chem. 268, 4604-4607 [Abstract/Free Full Text]
  46. Watson, P. A., Krupinski, J., Kempinski, A. M., and Frankenfield, C. D. (1994) J. Biol. Chem. 269, 28893-28898 [Abstract/Free Full Text]
  47. Wang, D. J., Huang, N. N., Gonzalez, F. A., and Heppel, L. A. (1991) J. Cell. Physiol. 146, 473-482 [Medline] [Order article via Infotrieve]
  48. Huang, N. N., Wang, D. J., Gonzalez, F., and Heppel, L. A. (1991) J. Cell. Physiol. 146, 483-494 [Medline] [Order article via Infotrieve]
  49. Huang, N. N., Wang, D. J., and Heppel, L. A. (1994) J. Biol. Chem. 269, 548-555 [Abstract/Free Full Text]

©1996 by The American Society for Biochemistry and Molecular Biology, Inc.